CD274 and neoplasm: To maximize treatment benefit and develop personalized therapeutic strategies, genomic and immune biomarkers, such as PD-L1 and tumor mutational burden (TMB), are utilized to guide therapeutic decisions based on tumor subtype [2, 3].